Insys Therapeutics (INSY) Stock Soars Today on Third Quarter Earnings Beat

NEW YORK (TheStreet) -- Shares of Insys Therapeutics, Inc.  (INSY) are surging, up 6.42% to $39.44 in late morning trading Tuesday, after the company reported third quarter earnings and revenue that beat analysts' estimates.

The Phoenix, AZ-based company posted third quarter net income of $11.5 million, or 31 cents per diluted share, compared to net income of $11.6 million, or 34 cents per diluted share from last year, but topping analysts' estimates of 29 cents per share.

The specialty pharmaceutical company posted revenue of $58.3 million for the period, up from $29.2 million in the third quarter of 2013, and surpassing the consensus estimate of $57.08 million in revenue. 

Insys Therapeutics develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules.

Separately, TheStreet Ratings team rates INSYS THERAPEUTICS INC as a Hold with a ratings score of C. TheStreet Ratings Team has this to say about their recommendation:

"We rate INSYS THERAPEUTICS INC (INSY) a HOLD. The primary factors that have impacted our rating are mixed, some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we find that the growth in the company's earnings per share has not been good."

INSY Chart INSY data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Starbucks Surprises Wall Street With U.S. Sales Up a Paltry 2%

Starbucks Surprises Wall Street With U.S. Sales Up a Paltry 2%

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Why Nashville, Denver, LA Should Reconsider Bids for Amazon HQ2

Why Nashville, Denver, LA Should Reconsider Bids for Amazon HQ2

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Jim Cramer: Visa Is a Technology Company That Masquerades as a Financial Company

Jim Cramer: Visa Is a Technology Company That Masquerades as a Financial Company